Raajit Rampal

Glad to share the finalized version of a Haematologica review by @raajitrampal.bsky.social and me focused on accelerated/blast-phase MPNs!

haematologica.org/article/view...

01.04.2025 15:05 — 👍 2    🔁 1    💬 0    📌 0

Hopefully this combination will emerge as a treatment option that will benefit our patients.

10.03.2025 19:36 — 👍 0    🔁 0    💬 0    📌 0

Overall, the study shows that RUX+PELA has clinical and biological effects beyond RUX alone, validating preclinical observations.

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

toxicity-wise, more anemia was observed with RUX alone, more thrombocytopenia with RUX+PELA, and more dysgeusia with RUX+PELA (but improved with dose modification)

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

Importantly, reduction of key cytokines (IL-8) and bone marrow fibrosis was better with combination than RUX alone.

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

MANIFEST-2 demonstrate that the combination of RUX+PELA was superior to RUX alone in spleen volume reduction (primary endpoint). Symptom burden reduction was similar between both arms.

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

ASCO Publications

a phase II study demonstrated that the BET inhibitor pelabresib in combination with RUX was tolerable and demonstrated efficacy beyond what was observed historically with RUX alone ascopubs.org/doi/full/10....

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms Genetic and functional studies underscore the central role of JAK/STAT signaling in myeloproliferative neoplasms (MPN). However, the mechanisms that mediate transformation in MPN are not fully delinea...

The key preclinical observations that led to investigation of BET inhibition in MF came from pmc.ncbi.nlm.nih.gov/articles/PMC... showing that NF-kB output and disease features in MF murine models were attenuated by BETi @rosslevinemd.bsky.social

10.03.2025 19:36 — 👍 0    🔁 0    💬 1    📌 0

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - Nature Medicine In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placeb...

Out today in
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social

10.03.2025 19:36 — 👍 3    🔁 2    💬 1    📌 1

@mskcancercenter.bsky.social cycle for survival! Time to ride and raise money for rare cancers

08.02.2025 13:58 — 👍 13    🔁 2    💬 1    📌 0

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD

1. Today the NIH director issued a new directive slashing overhead rates to 15%.

I want to provide some context on what that means and why it matters.

grants.nih.gov/grants/guide...

08.02.2025 00:18 — 👍 7061    🔁 4120    💬 259    📌 906

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....

07.02.2025 01:23 — 👍 16    🔁 7    💬 0    📌 0

Cycle for Survival: The Movement to Beat Rare Cancers Support rare cancer research at Memorial Sloan Kettering Cancer Center.

I just registered for Cycle for Survival to support MPN research at MSKCC. My ride is March 7 and I’m trying to raise as much as I can by then to help people with MPNs Make your 100% tax-deductible donation here secure2.convio.net/mskcc/site/T...

06.02.2025 20:47 — 👍 3    🔁 0    💬 0    📌 0

Epigenomic heterogeneity as a source of tumour evolution - Nature Reviews Cancer Single-cell epigenomic technologies are refining our understanding of cancer evolution.

#REVIEW

Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies.
📖 👉 https://bit.ly/40PCQ...

27.01.2025 15:13 — 👍 14    🔁 8    💬 0    📌 1